3.37

4.26% -0.15

After Hours: 3.37

Recursion Pharmaceuticals Inc (RXRX)

Overview News Price History Option Chain Financials Why RXRX Down? Discussions Forecast

Recursion Pharmaceuticals Inc stock is traded at $3.37, with a volume of 13.37M. It is down -4.26% in the last 24 hours and up +8.36% over the past month. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

Previous Close:

$3.52

Open:

$3.52

24h Volume:

13.37M

Relative Volume:

0.87

Market Cap:

$1.79B

Revenue:

$74.68M

Net Income/Loss:

$-644.76M

P/E Ratio:

-2.2726

EPS:

-1.4829

Net Cash Flow:

$-380.44M

1W Performance:

-1.17%

1M Performance:

+8.36%

6M Performance:

-32.06%

1Y Performance:

-29.13%

1-Day Range:

$3.32

$3.5579

1-Week Range:

$3.20

$3.59

52-Week Range:

$2.80

$7.18

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name

Recursion Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(385) 269-0203

Address

41S RIO GRANDE STREET, SALT LAKE CITY

Employee

600

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

RXRX's Discussions on Twitter

Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RXRX Recursion Pharmaceuticals Inc	3.37	1.87B	74.68M	-644.76M	-380.44M	-1.4829
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-17-25	Upgrade	JP Morgan	Neutral → Overweight
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight
May-22-23	Initiated	Morgan Stanley	Equal-Weight
Mar-16-23	Initiated	Needham	Buy
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-21	Initiated	Berenberg	Buy
May-11-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Goldman	Neutral
May-11-21	Initiated	JP Morgan	Neutral
May-11-21	Initiated	KeyBanc Capital Markets	Overweight
May-11-21	Initiated	SVB Leerink	Outperform

View All

Recursion Pharmaceuticals Inc Stock (RXRX) Latest News

May 05, 2026

Recursion earnings in focus as AI drug platform faces revenue test - Investing.com

May 05, 2026

Blake Borgeson sells 200,000 Class A shares (RXRX) under Rule 144 - Stock Titan

May 05, 2026

Recursion Pharmaceuticals Stock Short Interest Rises to 35.49% - Quiver Quantitative

May 05, 2026

May 04, 2026

Recursion Pharmaceuticals Inc expected to post a loss of 27 cents a shareEarnings Preview - TradingView

May 04, 2026

News Flash: 9 Analysts Think Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Earnings Are Under Threat - Sahm

May 04, 2026

May 03, 2026

Is It Time To Reconsider Recursion Pharmaceuticals (RXRX) After Recent Share Price Swings? - Yahoo Finance

May 03, 2026

Does Recursion’s 2026 Update And Board Shift Reframe Its AI Drug Discovery Ambitions For RXRX? - Sahm

May 03, 2026

What Makes Recursion Pharmaceuticals, Inc. (RXRX) A Strong Penny Stock - Insider Monkey

May 03, 2026

May 01, 2026

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts - Yahoo Finance

May 01, 2026

Assessing Recursion Pharmaceuticals (RXRX) Valuation As Investor Sentiment Splits On Future Prospects - Sahm

May 01, 2026

Recursion Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo

May 01, 2026

Recursion Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo

May 01, 2026

Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings - TechStock²

May 01, 2026

Apr 30, 2026

Recursion Pharmaceuticals : 2026 Proxy Statement - marketscreener.com

Apr 30, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $10.00 at JPMorgan Chase & Co. - MarketBeat

Apr 30, 2026

Recursion Pharmaceuticals Announces Planned Board Leadership Transition - TipRanks

Apr 30, 2026

Recursion Pharmaceuticals | DEFA14A: Others - Moomoo

Apr 30, 2026

[ARS] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan

Apr 30, 2026

Recursion (RXRX) outlines 2026 virtual meeting, board elections and pay votes - Stock Titan

Apr 30, 2026

Recursion founder exits board in June but stays on as adviser - Stock Titan

Apr 30, 2026

Recursion Pharmaceuticals | 8-K: Current report - Moomoo

Apr 30, 2026

Founder Chris Gibson to exit Recursion Pharmaceuticals (NASDAQ: RXRX) board - Stock Titan

Apr 30, 2026

Recursion Announces Board Transition - marketscreener.com

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

Apr 29, 2026

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance

Apr 29, 2026

RXRX stock soars pre-market on Q4 beat, Recursion CEO says company has ‘reached an inflection point’ - MSN

Apr 29, 2026

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 - marketscreener.com

Apr 29, 2026

Recursion opens May 6 earnings call to public questions online - Stock Titan

Apr 29, 2026

Apr 28, 2026

Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound? - MSN

Apr 28, 2026

Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell' (NASDAQ:RXRX) - Seeking Alpha

Apr 28, 2026

Recursion names Vicki Goodman as CMO - MSN

Apr 28, 2026

Apr 27, 2026

Recursion Pharmaceuticals May Be Losing Ground To Its Peers (NASDAQ:RXRX) - Seeking Alpha

Apr 27, 2026

Apr 26, 2026

Recursion Pharmaceuticals Projects Massive Growth Amid Clinical Success - HarianBasis.co

Apr 26, 2026

Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities - Insider Monkey

Apr 26, 2026

Recursion names Najat Khan CEO, succeeding co-founder Chris Gibson; stock down - MSN

Apr 26, 2026

Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market - MSN

Apr 26, 2026

Apr 25, 2026

Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast - Yahoo Finance

Apr 25, 2026

RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 25, 2026

10 Most Shorted Penny Stocks to Buy - Insider Monkey

Apr 25, 2026

Apr 24, 2026

A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention - Yahoo Finance

Apr 24, 2026

Recursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com India

Apr 24, 2026

Recursion Pharmaceuticals director Gibson sells $144,400 in stock - Investing.com

Apr 24, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 24, 2026

Recursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan

Apr 24, 2026

[SCHEDULE 13G/A] RECURSION PHARMACEUTICALS, INC. Amended Passive Investment Disclosure - Stock Titan

Apr 24, 2026

ETFs Investing in Recursion Pharmaceuticals, Inc. Class A Stocks - TradingView

Apr 24, 2026

AI-Driven Target Discovery Breakthrough Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX) - simplywall.st

Apr 24, 2026

Apr 22, 2026

Christopher Gibson sells Class A shares (NASDAQ: RXRX) in four filings - Stock Titan

Apr 22, 2026

Recursion Pharmaceuticals Uses AI to Accelerate Drug Development - HarianBasis.co

Apr 22, 2026